Stu Needleman, Chief Commercial Officer at Piramal Pharma Solutions, discusses the Biosecure Act and other big trends shaking up the industry, including GLP-1s, consolidation in the CDMO sector, and sterile fill-finish. He tells us more about Piramal’s $80-million expansion in Kentucky and how the company is adapting to the changes in the market. Check out the video!
Recommended
Related Content
China’s Biopharma Homecoming
September 1, 2026
7 min read
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han
The Mindset for Success in Biopharma's New Multipolar World
August 18, 2026
10 min read
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
Do Pharma Supply Chains Have a Visibility Problem?
August 4, 2026
4 min read
A recent multimillion-dollar freezer failure highlights the urgent need for real-time visibility across the pharmaceutical supply chain
The Confidentiality Barrier to AI-Enabled Drug Development
July 27, 2026
3 min read
AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck
